USA flag logo/image

An Official Website of the United States Government

Saliva Analyzer for Diagnosing SRD Patient Drug Use

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43DA032178
Solicitation Year:
2012
Solicitation Topic Code:
NIDA
Solicitation Number:
PA10-050
Small Business Information
Real-Time Analyzers
362 INDUSTRIAL PARK RD, #8 MIDDLETOWN, CT -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Saliva Analyzer for Diagnosing SRD Patient Drug Use
Agency: HHS
Contract: 1R43DA032178-01
Award Amount: $156,535.00
 

Abstract:

DESCRIPTION (provided by applicant): The overall aim of this SBIR program is to develop a surface-enhanced Raman spectroscopy (SERS) based device for on-site analysis of drugs in saliva. This device will allow immediate assessment of both medicinal and illicit drug use by patients with substance-related disorders (SRDs), and provide medical professionals and management with quantitative data so that treatment decisions can be made. Successful treatments for SRD patients require frequent monitoring of both medicinal and illicit drug use, which are mostly done in outpatient settings (doctor's office, rehabilitation centers, etc.) employing urine- based drug tests. For such tests, a sample is screened with immunoassay test kits, and if a drug is present, it isconfirmed and quantified by gas chromatography - mass spectrometry (GC-MS). Unfortunately, immunoassay test kits are susceptible to false positives, while the GC-MS method is time consuming and requires highly trained operators and a laboratory setting. Consequently, there is a critical need for a device that combines the portability, speed and ease-of-use of immunoassay kits with the identification and quantitation abilities of GC-MS so that health care personnel can assess SRD patient compliance in outpatient settings. The proposed SERS Saliva Analyzer (SSA) will meet all such requirements by providing health care personnel an easy-to-use device, which will extract, identify and quantify the presence of drugs (and metabolites) at requisite levels in saliva(1-50 ng/mL), within 10 minutes. The overall aim of the Phase I program is to demonstrate feasibility by detecting two priority drugs (cocaine and diazepam) in saliva at physiologically relevant concentrations and analysis time. This will be accomplishedby 1) measuring cocaine and diazepam at required sensitivity, and 2) measuring cocaine and diazepam in saliva. PUBLIC HEALTH RELEVANCE: The overall aim of this SBIR program is to develop a surface-enhanced Raman spectroscopy (SERS) based device foron-site analysis of drugs in saliva. This device will allow immediate assessment of both medicinal and illicit drug use by patients with substance-related disorders (SRDs), and provide medical professionals and management with quantitative data so that treatment decisions can be made.

Principal Investigator:

Stuart Farquharson
860-635-9800
STU@RTA.BIZ

Business Contact:

Stuart Farquharson
860-635-9800
stu@rta.biz
Small Business Information at Submission:

REAL-TIME ANALYZERS, INC.
362 INDUSTRIAL PARK RD, #8 MIDDLETOWN, CT -

EIN/Tax ID: 106163329
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No